| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00520-018-4501-X |
| P698 | PubMed publication ID | 30353228 |
| P2093 | author name string | Giuseppina Campisi | |
| Joel B Epstein | |||
| Jean-Jacques Body | |||
| Maria Kouri | |||
| Nikolaos Tsoukalas | |||
| Winston Tan | |||
| Sharon Elad | |||
| Rajesh V Lalla | |||
| Cesar Migliorati | |||
| Ourania Nicolatou-Galitis | |||
| Emmanouil Vardas | |||
| Dimitra Galiti | |||
| Erofili Papadopoulou | |||
| Kivanc Bektas-Kayhan | |||
| MASCC Bone Study Group | |||
| P2860 | cites work | Toxicity and response criteria of the Eastern Cooperative Oncology Group | Q29619399 |
| Is bisphosphonate-related osteonecrosis of the jaw an infection? A histological and microbiological ten-year summary. | Q33892631 | ||
| Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment? | Q35624101 | ||
| Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. | Q35978414 | ||
| Perceptions of medical doctors on bisphosphonate-related osteonecrosis of the jaw. | Q36125581 | ||
| Safety of long-term denosumab therapy: results from the open label extension phase of two phase 3 studies in patients with metastatic breast and prostate cancer | Q36345986 | ||
| A rare case of osteonecrosis of the jaw related to imatinib | Q36360226 | ||
| Osteonecrosis of the jaw associated with ziv-aflibercept | Q37525339 | ||
| Osteonecrosis of the jaw associated with everolimus: A case report | Q37701817 | ||
| Methodology for the MASCC/ISOO Mucositis Clinical Practice Guidelines Update | Q38041948 | ||
| Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. | Q38044141 | ||
| Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district | Q38583014 | ||
| Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: a systematic review and meta-analysis | Q38585389 | ||
| Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review | Q38603962 | ||
| Risk factors for medication-related osteonecrosis of the jaws: A systematic review. | Q38705715 | ||
| Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. | Q38776007 | ||
| Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology | Q38807483 | ||
| Osteonecrosis of the jaw a new complication related to Ipilimumab. | Q38865775 | ||
| Multiple myeloma vs. breast cancer patients with bisphosphonates-related osteonecrosis of the jaws: a comparative analysis of response to treatment and predictors of outcome | Q39686090 | ||
| Lack of cooperation between physicians and dentists during osteoporosis treatment may increase fractures and osteonecrosis of the jaw. | Q39895168 | ||
| Further development of the MRONJ minipig large animal model | Q40095548 | ||
| Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. | Q40481345 | ||
| Osteonecrosis of the Jaw in the Absence of Antiresorptive or Antiangiogenic Exposure: A Series of 6 Cases | Q40560466 | ||
| Learning from experience. Proposal of a refined definition and staging system for bisphosphonate-related osteonecrosis of the jaw (BRONJ). | Q42325555 | ||
| Bevacizumab-associated osteonecrosis of the jaw. | Q42536858 | ||
| Bevacizumab-related osteneocrosis of the jaw. | Q43194447 | ||
| Osteonecrosis of the maxilla associated with cancer chemotherapy in patients wearing dentures | Q44168630 | ||
| Osteonecrosis of the mandible associated with bevacizumab therapy. | Q45060836 | ||
| Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: a case series | Q45581692 | ||
| Rating the quality of evidence for clinical practice guidelines | Q46513734 | ||
| Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab | Q46535211 | ||
| A multicenter case registry study on medication-related osteonecrosis of the jaw in patients with advanced cancer | Q47252665 | ||
| Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors | Q47672449 | ||
| Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: conservative treatment is effective up to stage 2. | Q48707778 | ||
| Osteonecrosis of the jaw (ONJ) in patients who receive Bone Targeting Agents (BTAs): the power of e-learning | Q49884526 | ||
| Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort. | Q49990599 | ||
| Stage-specific therapeutic strategies of medication-related osteonecrosis of the jaws: a systematic review and meta-analysis of the drug suspension protocol | Q50053219 | ||
| Axitinib-related osteonecrosis of the jaw. | Q50054402 | ||
| Osteonecrosis of the jaw in a patient receiving cabozantinib. | Q51071178 | ||
| Osteonecrosis of the Jaw in Association With Chemotherapy in the Setting of Cutaneous T-Cell Lymphoma. | Q52922799 | ||
| Regorafenib Also Can Cause Osteonecrosis of the Jaw. | Q52985112 | ||
| Osteonecrosis of the jaw related to everolimus: a case report. | Q53313578 | ||
| Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. | Q54449449 | ||
| Osteonecrosis of the jaw related to sunitinib. | Q54680163 | ||
| Delayed Diagnosis of Osteonecrosis of the Jaw (ONJ) Associated with Bevacizumab Therapy in Colorectal Cancer Patients: Report of Two Cases. | Q55094789 | ||
| Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature. | Q55332559 | ||
| American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update | Q56565081 | ||
| Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: Report of 2 cases with clinical implications | Q57904464 | ||
| Osteonecrosis of the Jaw Related to Bevacizumab | Q60386785 | ||
| Osteonecrosis of the jaws and bevacizumab therapy: a case report | Q61775067 | ||
| Osteonecrosis of the jaw in oncology patients treated with bisphosphonates: prospective experience of a dental oncology referral center | Q84216155 | ||
| Sunitinib related osteonecrosis of jaw: a case report | Q84323419 | ||
| A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit | Q84818261 | ||
| Osteonecrosis of the jaw in patients treated with oral and intravenous bisphosphonates: experience in Sweden | Q87421527 | ||
| Osteonecrosis of the Jaw in a Breast Cancer Patient Treated with Everolimus and a Single Dose of Zoledronic Acid | Q87633265 | ||
| Medication-related osteonecrosis of the jaw associated with aflibercept | Q88913700 | ||
| Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners | Q89921984 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 383-394 | |
| P577 | publication date | 2018-10-23 | |
| P1433 | published in | Supportive Care in Cancer | Q15766919 |
| P1476 | title | Osteonecrosis of the jaw related to non-antiresorptive medications: a systematic review | |
| P478 | volume | 27 |
Search more.